Interview with Germano Carganico, General Manager, Toscana Life Sciences
Italians are often praised to make up deficiencies of the country at national level with more creativity at a regional level- which is why Science Parks are coordinated at the…
Assogenerici (National Association of Generic Drugs Industries) is the official representative body of the industry of generic drugs and biosimilars in Italy, at the forefront in providing medicines at affordable prices and high quality for millions of citizens, helping to boost competition and innovation in the pharmaceutical sector. Associated companies both small and medium corporations for a wide range of drugs, by perfusion with Galen to traditional generics to cutting biosimilars, is distributed in pharmacies at public hospitals.
Established in 1993, Assogenerici represents over 50 pharmaceutical companies. The companies represented in Assogenerici provide 10,000 direct jobs in Italy over the important induced, highly specialized. Generic drugs generate over € 400 million of savings per year for the NHS and for patients, helping to ensure patient access to essential drugs releasing at the same time, valuable resources for new and expensive drug therapies.
Assogenerici plays an important advisory role in the Italian health sector. Assogenerici and its members are working with the Italian and European institutions to develop sustainable solutions for pharmaceutical care and to increase the competitive strength of Italy in the world pharmaceutical market.
Passeggiata di Ripetta, 22 – int. 1 – 00186 – Roma
Tel: +39.06.59.60.53.24
Fax: +39.06.54.31.323
E-mail: info@assogenerici.it
Posta Elettronica Certificata: assogenerici@pec.
Web: assogenerici.it
Italians are often praised to make up deficiencies of the country at national level with more creativity at a regional level- which is why Science Parks are coordinated at the…
Italfarmaco counts amongst the few players who really sustained the growth of the Italian pharmaceutical industry in the past 10 years. Which specific values would you quote as keys to…
You created Abiogen in 1997, following the acquisition of Istituto Gentili by MSD, in order to maintain your family’s entrepreneurial tradition, keeping building on the legacy of your great-grandfather Commendatore…
Recordati was created in 1926, and the combined work of three generations turned the small laboratory not only into a local success story but also a broad European Group. Your…
Following the successful result of the “Piano Sanitario Nazionale” 2005 – 2008, could you introduce to ours readers the key priorities and main health policies to be implemented by 2009…
Following 20 years of a comprehensive experience in diverse fields of the pharmaceutical industry, you entered Baxter in 2000. At the time, the Italian affiliate was already a well established…
Despite Italy being one of the most important pharmaceutical markets not only in Europe but also in the World, the industry remained quite stable for the last two years and…
Grunenthal-Formenti relies on Formenti’s 60 years experience in Italy and is the result of the merger of both the German and Italian entities in 96. How would you describe the…
Having led a 26 years long career in Pfizer, you have been involved in a number of different countries including leading markets such as the US and Japan, but also…
You have worked in other countries such as the UK and the US with very large and significant pharmaceutical industries. What would you say is particular about the Italian pharmaceutical…
Since 1982, CNR has been the Italian public body which most contributed to the creation of inventions and innovations. What have been the main strategies behind such a success in…
Over more than 25 years, PAREXEL has expanded its global footprint through a combination of organic growth, alliances, and acquisitions. What was the rationale behind entering Italy in 1995 and…
See our Cookie Privacy Policy Here
